Marshall Wace’s AbbVie ABBV Stock Holding History

Marshall Wace’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-106,000	Closed	-$16.4M	–	2388
2023 Q4	$16.4M	Buy	+106,000	New	+$15.5M	0.03%	535
2023 Q3	–	Sell	-28,400	Closed	-$3.83M	–	2130
2023 Q2	$3.83M	Buy	+28,400	New	+$4.16M	0.01%	1138
2023 Q1	–	Sell	-5,100	Closed	-$824K	–	2586
2022 Q4	$824K	Sell	5,100 -3,900	-43%	-$598K	﹤0.01%	2170
2022 Q3	$1.21M	Buy	+9,000	New	+$1.29M	﹤0.01%	2310
2021 Q2	–	Sell	-600	Closed	-$65K	–	2595
2021 Q1	$65K	Buy	+600	New	+$64.2K	﹤0.01%	2379

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Marshall Wace's ABBV Position: Q2 2026 in Review

Marshall Wace increased its AbbVie (ABBV) stake by 281,758% in Q2 2026, buying an estimated $643M and bringing the position to 2,990,512 shares worth $753M. The position accounts for 0.59% of the portfolio, ranked #17.

Marshall Wace first reported a position in ABBV in Q3 2014 and has held it in 39 quarters since. 4,216 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Marshall Wace held 2,990,512 shares of AbbVie worth $753M as of Q2 2026.
Marshall Wace bought 2,989,451 AbbVie shares in Q2 2026, an estimated $643M.
AbbVie made up 0.59% of Marshall Wace's portfolio in Q2 2026, its #17 holding.
Marshall Wace first reported a position in AbbVie in Q3 2014 and has held it in 39 quarters since.
4,216 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.